Corifollitropin Alfa
| 證據等級: L5 | 預測適應症: 8 個 |
目錄
Corifollitropin Alfa: From Controlled Ovarian Stimulation to Gastroduodenitis
One-Sentence Summary
Corifollitropin alfa is a long-acting recombinant FSH receptor agonist used in controlled ovarian stimulation (COS) for assisted reproductive technology. The TxGNN model predicts potential effectiveness for Gastroduodenitis, but this direction is currently supported by 0 clinical trials and 0 relevant publications — it is a model-prediction-only signal with no mechanistic or clinical corroboration.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Controlled ovarian stimulation (COS) for infertility/assisted reproductive technology (based on known pharmacology; no Finland license data available to source this from) |
| Predicted New Indication | Gastroduodenitis |
| TxGNN Prediction Score | 99.65% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Finland Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (marked as a High-severity data gap in the source evidence pack). Based on known pharmacology, corifollitropin alfa is a long-acting recombinant follicle-stimulating hormone (FSH) receptor agonist; its activity is restricted to FSH receptors on ovarian granulosa cells, where it drives follicular development during controlled ovarian stimulation.
Gastroduodenitis is a mucosal inflammatory condition of the stomach and duodenum, with pathophysiology centered on gastric acid secretion, mucosal barrier integrity, and local inflammatory/infectious processes (e.g., H. pylori). There is no established pharmacological pathway connecting ovarian FSH receptor agonism to gastroduodenal mucosal inflammation.
The evidence pack's own mechanistic assessment concurs: the TxGNN score (99.65%) reflects graph-embedding similarity rather than a validated biological relationship, and no clinical or literature evidence has been found to substantiate this link. This prediction should be treated as a low-confidence signal warranting no near-term action.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Finland Market Information
Corifollitropin alfa is not currently marketed in Finland (market status: 未上市; 0 marketing authorizations on file), so no product/authorization details are available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is based solely on TxGNN model scoring (L5, S0) with no clinical trials, no supporting literature, and no plausible mechanistic link between FSH receptor agonism and gastroduodenal inflammation. All other predicted indications for this drug (migraine, peptic ulcer disease, Raynaud disease, pulmonary hypertension, kyphoscoliotic heart disease) are similarly rated L5/Hold with no corroborating evidence — including one candidate (migraine susceptibility) where 20 literature hits were found but, on review, are epilepsy/migraine genetics papers unrelated to corifollitropin alfa (keyword-matching noise, not real evidence).
To proceed, the following is needed:
- TFDA/regulatory package insert data (currently a Blocking-severity data gap — required before any safety pre-assessment)
- Confirmed mechanism of action data from DrugBank or primary literature
- Preclinical or mechanistic studies establishing biological plausibility for the gastrointestinal indication
- Re-screening against updated literature/clinical trial databases before reconsidering this candidate
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.